The FDA enforcement report on a software defect in several Dexcom (DXCM) CGM iOS and watchOS apps has pushed product reliability and recall risk to the foreground for DexCom stock investors.

Despite the recall related to its CGM apps, DexCom's recent trading has been relatively resilient, with a 1 month share price return of 20.2% and a year to date share price return of 10.82%. However, the 1 year total shareholder return is down 13.76%, suggesting that shorter term momentum contrasts with weaker longer term outcomes.

If this kind of health tech news has you thinking about where digital medicine could go next, it may be worth scanning 39 healthcare AI stocks for more potential ideas.

That mix of recall headlines, solid reported revenue and net income, and a share price still trading at a reported 35% intrinsic discount sets up the core question for you: Is this a buying opportunity, or is the market already pricing in future growth?

Most Popular Narrative: 9.7% Undervalued

DexCom's most followed narrative pegs fair value at $81.64, compared with the last close of $73.74. This puts the recall headlines up against a still supportive long term earnings story.

The recent expansion of insurance reimbursement for type 2 non-insulin diabetes patients, now covering nearly 6 million lives across the three largest U.S. PBMs, opens a large, previously untapped segment of DexCom's addressable market, driving new patient growth and supporting robust multi-year revenue expansion. Growing global recognition of CGM efficacy, with recent clinical trial evidence and expanded coverage in international markets (e.g., France, Japan, and Ontario, Canada), positions DexCom to penetrate underpenetrated regions and diversify revenue streams, creating sustainable top-line growth.

Want to see what kind of long term revenue ramp and profit margin profile justifies that valuation gap? The core narrative hinges on steady growth assumptions, higher earnings power and a premium earnings multiple that has been stress tested across different scenarios.

Result: Fair Value of $81.64 (UNDERVALUED)

However, this depends on Medicare pricing and competition not becoming too aggressive, since CMS bidding and rival CGM or sensor platforms are both capable of compressing margins and limiting upside.

Another Way To Look At Valuation

While the narrative and fair value work suggest DexCom is 9.7% undervalued, the P/E picture looks less forgiving. The stock trades on a 30.6x P/E versus a fair ratio of 29.7x, the US Medical Equipment industry at 24.2x and peers at 21.1x, which points to valuation risk if sentiment cools.

For a closer look at how this stacks up against earnings power and sector benchmarks, See what the numbers say about this price — find out in our valuation breakdown.

Next Steps

If this mix of risks and optimism has you weighing both sides, do not wait to check the details and form your own view. Be sure to review the 3 key rewards for more information.

Looking for more investment ideas?

If you are serious about sharpening your portfolio, do not stop at one stock. Use the Simply Wall St Screener to spot clear, data backed ideas before others do.

• Target income potential by reviewing companies in the 10 dividend fortresses that may offer higher yields with more robust payouts.
• Hunt for potential value opportunities using the 46 high quality undervalued stocks to see stocks where quality and pricing currently look out of sync.
• Prioritize peace of mind by focusing on the 64 resilient stocks with low risk scores and see which stocks score well on resilience and financial strength.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.